TY - JOUR
T1 - Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates
AU - Méndez-Samperio, Patricia
N1 - Publisher Copyright:
© 2019 The Foundation for the Scandinavian Journal of Immunology
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Bacillus Calmette-Guérin (BCG) remains the only licensed vaccine against human tuberculosis (TB). BCG is a live-attenuated strain of Mycobacterium bovis, with limitations in efficacy against respiratory TB, the most common form of the disease responsible for transmission. However, continues to be used in the immunization programmes of different countries in the absence of another alternative. In order to improve BCG efficacy against pulmonary TB, in the current clinical TB vaccine pipeline, there are live-attenuated TB vaccines to replace BCG. This review discusses the current status of the development of live vaccine candidates designed to replace BCG from the rational strategies and immunological challenges to its clinical trial and identify key areas in the next years considered essential to confer improved safety and efficacy over BCG.
AB - Bacillus Calmette-Guérin (BCG) remains the only licensed vaccine against human tuberculosis (TB). BCG is a live-attenuated strain of Mycobacterium bovis, with limitations in efficacy against respiratory TB, the most common form of the disease responsible for transmission. However, continues to be used in the immunization programmes of different countries in the absence of another alternative. In order to improve BCG efficacy against pulmonary TB, in the current clinical TB vaccine pipeline, there are live-attenuated TB vaccines to replace BCG. This review discusses the current status of the development of live vaccine candidates designed to replace BCG from the rational strategies and immunological challenges to its clinical trial and identify key areas in the next years considered essential to confer improved safety and efficacy over BCG.
KW - bacillus Calmette-Guérin
KW - immune response
KW - infection
KW - tuberculosis
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85066091922&partnerID=8YFLogxK
U2 - 10.1111/sji.12772
DO - 10.1111/sji.12772
M3 - Artículo de revisión
C2 - 31055842
AN - SCOPUS:85066091922
SN - 0300-9475
VL - 90
JO - Scandinavian Journal of Immunology
JF - Scandinavian Journal of Immunology
IS - 4
M1 - e12772
ER -